Literature DB >> 6549771

Penicillin prophylaxis in children with cardiac disease: postextraction bacteremia and penicillin-resistant strains of viridans streptococci.

J Hess, Y Holloway, J Dankert.   

Abstract

The incidence of postextraction bacteremia in 82 children with dental foci and cardiac disease given parenteral penicillin prophylaxis was assessed 5 min after extraction. Penicillin concentrations were determined in blood samples obtained at the same time. Before extraction, cultures were taken from the gingival sulcus. Postextraction bacteremia occurred in 21% of the patients and was due to penicillin-sensitive microorganisms in 10 and to both penicillin-sensitive and penicillin-resistant microorganisms in seven children. In three of these children penicillin-resistant viridans streptococcal strains were isolated. Penicillin-resistant viridans streptococci were present in the gingival sulcus flora of 39% of the children, but a relationship between the presence of such strains in the gingival sulcus and the occurrence of postextraction bacteremia could not be demonstrated. There was no difference in the serum penicillin concentrations found in children with bacteremia due to penicillin-sensitive or penicillin-resistant microorganisms, or between the concentrations in children with and without bacteremia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6549771     DOI: 10.1093/infdis/147.1.133

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Failure of vancomycin prophylaxis and treatment for Actinobacillus actinomycetemcomitans endocarditis.

Authors:  R H Eng; S M Smith; E J Goldstein; K T Miyasaki; S E Quah; F Buccini
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

Review 2.  Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children.

Authors:  B Capitano; R Quintiliani; C H Nightingale; D P Nicolau
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.